Skip to main content
. Author manuscript; available in PMC: 2019 Jul 17.
Published in final edited form as: Circulation. 2018 Feb 5;138(3):287–304. doi: 10.1161/CIRCULATIONAHA.117.031258

Fig. 7. Demonstration of the therapeutic relevance of the miR-34a-3p-MiD pathway in preclinical model.

Fig. 7

Fig. 7

(A) Representation of the proposed miR-MiDs pathway in PAH relative to normal. (B) Decreased expression of miR-34a-3p in PAH patients leads to increased expression of the Drp1 binding partners MiD49 and MiD51 which in turn increases mitotic fission and promotes cell proliferation.